Table 2.
Main characteristics of studies including patients with cirrhosis and acute upper gastrointestinal bleeding due to peptic ulcers
|
Ref.
|
Patients (n)
|
Cirrhotic patients with NVAGIB (n)
|
Non-variceal bleeding source: peptic ulcer/other (n)
|
Patients received endoscopic treatment (n)
|
Endoscopic treatment modality (n)
|
Failure to control bleeding, n (%)
|
Rebleeding, n (%)
|
Mortality, n (%)
|
Rescue therapy
|
| Seo et al[18] | 464 | 76 | GU: 48; DU: 16; OL: 12 | 48 | EC: 201 | 1/76 (1.3%) | 2/76 (2.6%) | 42 d: 11/76 (14.5%) | NR |
| González-González et al[22] | 160 | 160 | GU: 39; DU: 33; GU + DU: 9; EU: 3 | 43 | EI: 7; BICAP EC: 6; CT: 30 | NR | 3/160 (1.9%) | In-hospital: 22 (13.8%) | S: 0 |
| Rudler et al[23] | 203 | 29 | DU: 19; GU: 7; MU: 3 | 20 | EI: 9; EI + HC: 11 | NR | 2/29 (7%) | 30 d: 1/29 (3%) | AE: 3; S: 0 |
| Morsy et al[24] | 532 | 93 | DU: 25; EU: 5; GU: 3 | 42 | EI: 23; APC: 19 | NR | 4/93 (4.3%) | In-hospital: 13/93 (14%) | NR |
| Yang et al[19] | 210 | 210 | GU: 133; DU: 66; GU + DU: 11 | 210 | EI: 80; APC: 41; HC: 13; EI + APC: 36; EI + HC: 40 | 7 (3.3%) | 47 (22.4%) | In-hospital: 37/210 (17.6%) | NR |
| Kuo et al[20] | 235 | 235 | GU:146; DU: 73; GU + DU: 16 | 235 | EI: 84; APC: 50; HC: 20; CT: 81 | 8 (3.4%) | 48 (20.4%) | In-hospital: 40/235 (17%) | NR |
| Ardevol et al[21] | 790 | 144 | DU: 79; GU: 62; SU: 3 | 88 | EI: NR; Multipolar EC: NR; HC: NR; EIS: NR | 14 (10%) | 15 (10%) | 6 wk: 24/144 (17%) | SET: 11; AE: 3; S: 2 |
1
Endoscopic treatment modality only mentioned for 20/48 patients;
NVAGIB: Non-variceal acute gastrointestinal bleeding; GU: Gastric ulcer; DU: Duodenal ulcer; EU: Esophageal ulcer; OL: Other lesions; MU: Multiple ulcers; EC: Electrocoagulation; EI: Epinephrine injection; HC: Hemoclips; CT: Combination therapy; APC: Argon plasma coagulation; EIS: Endoscopic injection sclerotherapy; NR: Not reported; S: Surgery; AE: Arterial embolisation; SET: Second endoscopic treatment.